Zogenix, Inc. provided earnings guidance for the fourth quarter ended December 31, 2013. The company announced preliminary unaudited gross product sales on sales of SUMAVEL(R) DosePro(R) for the quarter ended December 31, 2013. The company expects to report fourth quarter 2013 gross product sales of approximately $14 million on 141,780 units shipped, with unit volume up approximately 2.2% sequentially from third quarter 2013.

The company announced preliminary unaudited net product revenue on sales of SUMAVEL DosePro for the fourth quarter 2013 of approximately $9 million, up approximately 30% sequentially from $6.9 million in the third quarter 2013, which included a $2.4 million increase to the company's estimate of future product returns. This does not include other revenue related to the service fee received by the company for its co-promotion of Migranal(R) Nasal Spray. Gross margin for the fourth quarter 2013 is expected to be impacted by a one-time charge of approximately $1.3M due to scrap and excess capacity.